NCT04709796View on ClinicalTrials.gov

The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients

NARecruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
IVFEmbryo LossMiscarriage, Recurrent
Interventions
DRUG

EmbryoGlue®, Vitrolife

The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.

DRUG

Conventional Transfer

The control arm is the conventional embryo transfer without Embryo glue medium

Trial Locations (1)

9000

RECRUITING

UZ Ghent, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER